CCL2 and cancer: Accordingly, downregulation of CCL2 expression enhanced CD8+ T cell-mediated antitumor immunity, which mitigates cancer immunosuppression and overcomes PD-1 immunotherapy resistance by inhibiting TAM and G-MDSC infiltration.